Last reviewed · How we verify
NCT05711901: MINERVA
Selective Lipopolysaccharide Hemosorption in Maternal Sepsis
NA trial testing Efferon LPS in Maternal sepsIs in 30 participants. Completed in 15 June 2024.
1 June 2024
Quick facts
| Lead sponsor | Efferon JSC |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 January 2022 |
| Primary completion | 1 June 2024 |
| Estimated completion | 15 June 2024 |
| Sites | 7 locations across Russia |
Drugs / interventions tested
- Efferon LPS
Conditions studied
- Maternal sepsIs — all drugs for Maternal sepsIs →
Sponsor
Efferon JSC
Who can join
18 and older, female only, with Maternal sepsIs. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
One of the major health problems in the world is sepsis, the number of cases of which, according to WHO, annually reaches 20-30 million. The prevalence and frequency of obstetric sepsis are quite pronounced. Thus, in Europe, up to 500,000 cases of sepsis are registered annually. In Russia, the frequency of obstetric purulent-inflammatory diseases in the structure of maternal mortality ranges from 5 to 26%, according to some data - up to 45-75%. In the structure of maternal mortality, this pathology is in second or third place. Numerous studies have shown that the use of extracorporeal sorption methods that eliminate endotoxin and cytokines improves the results of treatment of patients with septic shock. The main goal of the study was to obtain new data on the efficacy and safety of using the Efferon LPS device for hemosorption of lipopolysaccharides during extracorporeal detoxification in patients with obstetric sepsis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05711901
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Efferon LPS
Trials testing the same drug.
- NCT07532174 — Efferon LPS Hemoadsorption in Cardiac Surgery Patients · NA · recruiting
- NCT07267169 — Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis · NA · recruiting
- NCT07383597 — Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease · NA · not yet recruiting
- NCT07259668 — Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns · recruiting
- NCT06659289 — Hemoperfusion Efferon LPS During Cardiac Surgery Using Cardiopulmonary Bypass · NA · terminated
Other Efferon JSC trials
Trials by the same sponsor.
- NCT07532174 — Efferon LPS Hemoadsorption in Cardiac Surgery Patients · NA · recruiting
- NCT07267169 — Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis · NA · recruiting
- NCT07383597 — Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease · NA · not yet recruiting
- NCT07259668 — Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns · recruiting
- NCT07248930 — Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Thermal Burns · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05711901 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Efferon JSC
- Last refreshed: 25 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05711901.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing